Special Issue "Prospects for the Medical Therapeutic Development of Umbilical Cord Blood"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Translational Medicine".

Deadline for manuscript submissions: 30 January 2024 | Viewed by 86

Special Issue Editor

Department of Pediatrics Hem-Oncology, School of Medicine, University of Virginia, Charlottesville, VA, USA
Interests: leukemia; stem cell; gene expression; translational research

Special Issue Information

Dear Colleagues,

Regenerative medicine is area of research that involves the “regeneration” of damaged, diseased and dysfunctional organs, tissues or cells due to aging, injury or disease. The development of stem cell research has been central to the field of regenerative medicine in recent years. Umbilical cord blood (UCB) has proven to be a rich source of mesenchymal and hematopoietic stem cells, a source that can be obtained at the time of birth. Collecting stem cells from umbilical cord blood (UCB) is fairly easy, as it does not involve an invasive procedure and it is mostly ethically non-controversial. UCB obtained at birth can be frozen and stored long-term for future clinical use. UCB is relatively less prone to transmission via viral infection and somatic mutations after clinical transplantation, which makes it a very promising material for broader clinical use in regenerative medicine. In this Special Issue of Medicina, we intend to introduce concepts and basic and clinical research related to the utility of umbilical cord blood in medical therapeutics, along with its current clinical uses. For this Special Issue, we invite authors to submit their original research articles, technical notes, meta-analyses, and review articles on evolving concepts in the uses of UCB as a source of stem cells and in therapeutics. They can include all areas of UCB, such as the safety of UCB treatments, cellular heterogeneity, improvements in isolation efficiency, ex vivo expansion of cord-blood-derived stem cells, advanced therapy development, clinical trials using UCB, bioprocessing, and basic research.

Dr. Praveen Kumar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • the safety of UCB treatments
  • cellular heterogeneity
  • improvements in isolation efficiency
  • ex vivo expansion of cord-blood-derived stem cells
  • advanced therapy development
  • clinical trials using UCB, bioprocessing, and basic research

Published Papers

This special issue is now open for submission.
Back to TopTop